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HPLC purity determination. Compounds were analyzed for purity (HPLC) using Agilent 1200 HPLC system 
equipped with a Quat Pump (G1311B), an injector (G1329B) 1260 ALS, TCC 1260 ( G1316A) and a detector 
1260 DAD VL+ (G1315C). Compounds were dissolved in methanol, final concentrations were ~ 1mg/mL.  
HPLC analysis was performed in two diverse systems for each compound.  
Method A. Zorbax Eclipse Plus C18 4.6 × 150mm, 1.8µ, S.N. USWKY01594 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis 
were performed at 280 nm for compounds 24 – 26 and 29 – 31; at 290 nm for compounds 28, 33, 34 and 41 and 
at 320 nm for compounds 42 – 46. Flow rate was 0.5 mL/min.  
Compounds 24 – 26 and 29 – 31 were eluted using gradient protocol: 0–0.5 min 95% A, 0.5–3  min 95% A→ 
5% A, 3–13 min  5% A, 13–14 min 5% A→ 95% A, 14–16 min 95% A. 
Compound 28 was eluted using gradient protocol: 0–1.5 min 95% A, 1.5–5 min  95% A→ 5% A, 5–16 min  5% 
A, 16–18 min 5% A→ 95% A, 18–21 min 95% A. 
Compounds 33 and 34 were eluted using gradient protocol: 0–1.5 min 95% A, 1.5–5 min 95% A→ 5% A, 5–16 
min  5% A, 16–18 min 5% A→ 95% A, 18–20 min 95% A. 
Compound 41 was eluted using gradient protocol: 0–1.5 min 95% A, 1.5–5 min 95% A→ 5% A, 5–16 min  5% 
A, 16–18 min 5% A→ 95% A. 
Compounds 42 – 46 were eluted using gradient protocol: 0–1 min 95% A, 1–5 min 95% A→ 5% A, 5–16 min  
5% A, 16–18 min 5% A→ 95% A. 
Method B. Zorbax Eclipse Plus C18 4.6 × 150mm, 1.8µ, S.N. USWKY01594 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis were 
performed at 280 nm for compounds 24 – 26 and 29 – 31; at 290 nm for compounds 28, 34 and 41 and at 320 
nm for compounds 32 and 42 – 46. Flow rate was 0.5 mL/min.  
Compounds 24 – 26 and 29 – 31 were eluted using gradient protocol: 0–0.5  min 95% A, 0.5–3 min 95% A→ 
5% A, 3–13 min  5% A, 13–14 min 5% A→ 95% A, 14–16 min 95% A. 
Compound 28 was eluted using gradient protocol: 0–1.5 min 95% A, 1.5–5 min  95% A→ 5% A, 5–16 min  5% 
A, 16–18 min 5% A→ 95% A, 18–21 min 95% A. 
Compound 32 was eluted using gradient protocol: 0–1 min 95% A, 1–5 min 95% A→ 5% A, 5–14 min  5% A, 
14–15 min 5% A→ 95% A, 15–16 min 95% A. 
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Compound 34 was eluted using gradient protocol: 0–1.5 min 95% A, 1.5–5 min  95% A→ 5% A, 5–16 min  5% 
A, 16–18 min 5% A→ 95% A, 18–20 min 95% A. 
Compounds 41 – 46 were eluted using gradient protocol: 0–1 min 95% A, 1–5 min 95% A→ 5% A, 5–16 min  
5% A, 16–18 min 5% A→ 95% A. 
Method C. Zorbax Eclipse Plus C18 2.1 × 100mm, 1.8µ, S.N. USUXU04444 was used as the stationary phase. 
Eluent was made of the following solvents: water (A) and methanol (B). The analysis were performed at 320 
nm for compound 32. Flow rate was 0.5 mL/min.  
Compound 32 was eluted using gradient protocol: 0–1 min 95% A, 1–5 min 95% A→ 5% A, 5–14 min  5% A, 
14–15 min 5% A→ 95% A, 15–16 min 95% A. 
Method D. Poroshell 120 EC-C18, 4.6 × 50mm, 2.7µ, S.N. USCFU07797 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis 
were performed at 290 nm for compound 33 and 280 nm for compounds 27 and 38. Flow rate was 1 mL/min. 
Compound 33 was eluted using gradient protocol: 0–0.5 min 95% A, 0.5–3 min 95% A→ 5% A, 3–13 min 5% 
A, 13–14 min 5% A→ 95% A, 14–15 min 95% A. 
Compounds 27 and 38 were eluted using gradient protocol: 0–0.5 min 95% A, 0.5–1.5 min 95% A→ 5% A, 
1.5–8 min 5% A, 8–9 min 5% A→ 95% A, 9–10 min 95% A. 
Method E. Zorbax Eclipse Plus C18 4.6 × 150mm, 1.8µ, S.N. USWKY01594 was used as the stationary phase. 
Eluent was made of the following solvents: water (A) and acetonitrile (B). The analysis were performed at 280 
nm for compound 37 and at 290 nm for compounds 35 and 36. Flow rate was 0.5 mL/min.  
Compounds 35 and 36 were eluted using gradient protocol: 0–1 min 95% A, 1–6 min 95% A→ 5% A, 6–13 
min 5% A, 13–14 min 5% A→ 95% A, 14–17 min 95% A. 
Compound 37 was eluted using gradient protocol: 0–1 min 95% A, 1–5 min 95% A→ 5% A, 5–16 min 5% A, 
16–17 min 5% A→ 95% A, 17–18 min 95% A. 
Method F. Zorbax Eclipse Plus C18 4.6 × 150mm, 1.8µ, S.N. USWKY01594 was used as the stationary phase. 
Eluent was made of the following solvents: water (A) and methanol (B). The analysis were performed at 290 
nm for compounds 35 and 36 and at 280 nm for compound 37. Flow rate was 0.5 mL/min.  
Compounds 35 and 36 were eluted using gradient protocol: 0–1 min 95% A, 1–6 min 95% A→ 5% A, 6–13 
min 5% A, 13–14 min 5% A→ 95% A, 14–17 min 95% A. 
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Compound 37 was eluted using gradient protocol: 0–1 min 95% A, 1–5 min 95% A→ 5% A, 5–16  min 5% A, 
16–17 min 5% A→ 95% A, 17–18 min 95% A. 
Method G. Zorbax Eclipse Plus C18 2.1 × 100mm, 1.8µ, S.N. USUXU04444 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis were 
performed at 295 nm for compounds 39 and 40. Flow rate was 0.5 mL/min. 
Compounds 39 and 40 were eluted using gradient protocol: 0–1 min 95% A→ 5% A, 1–7 min  5% A, 7–8 min 
5% A→ 95% A, 8–10 min 95% A. 
Method H. Zorbax Eclipse Plus C18 2.1 × 100mm, 1.8µ, S.N. USUXU04444 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and acetonitrile (B). The analysis 
were performed at 295 nm for compound 39. Flow rate was 0.5 mL/min. 
Compound 39 was eluted using gradient protocol: 0–1 min 95% A→ 5% A, 1–7 min  5% A, 7–8 min 5% A→ 
95% A, 8–10 min 95% A. 
Method I. Poroshell 120 EC-C18, 4.6 × 50mm, 2.7µ, S.N. USCFU07797 was used as the stationary phase. 
Eluent was made of the following solvents: 0.2% formic acid in water (A) and methanol (B). The analysis were 
performed at 280 nm for compounds 27 and 38 and at 295 nm for compound 37. Flow rate was 0.5 mL/min. 
Compounds 27 and 38 were eluted using protocol: 0–0.5 min 95%A, 0.5–1.5 min 95% A→ 5% A, 1.5–8 min 
5% A, 8–9 5% A→ 95% A, 9–10 min 95% A. 
Compound 40 was eluted using protocol: 0–1 min 95%A, 1–2 min 95% A→ 5% A, 2–10 min 5% A, 10–11 5% 
A→ 95% A, 11–12 min 95% A. 
General procedure A for synthesis of 4-(alkylthio)anilines 13 – 161 
The appropriate alkylthiol (1.5 eq) was added to the mixture containing 1-chloro-4-nitrobenzene (1 eq), 
potassium hydroxide (3 eq) and PEG as a solvent. The reaction mixture was stirred at 100 °C for 3.5 h and then 
poured onto the water. After the extraction with ethyl acetate, combined organic layers were dried over 
anhydrous Na2SO4, filtered and evaporated to dryness. The crude product was subjected to silica gel column 
chromatography using hexane/ethyl acetate as eluent to afford the final product.  
General procedure B for synthesis of 6-(alkylsulfanyl)-1,3-benzothiazol-2-amines 19 – 22: A solution of 
bromine (1.25 eq) in acetic acid was added to a stirring mixture of an appropriate 4-(alkylthio)aniline (1 eq), 
ammonium thiocyanate (4 eq), acetic acid and water at 10 °C. The reaction mixture was stirred at room 
temperature for 18 h, and then at 80 °C for 3 h. After cooling to room temperature, the reaction mixture was 
poured onto water and Na2CO3 was added in order to adjust pH to 5-6. The reaction mixture was extracted with 
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ethyl acetate, layers were separated and organic layer was washed with brine. Organic layer was dried over 
anhydrous Na2SO4, filtered and evaporated to dryness. The crude product was subjected to silica gel column 
chromatography using CH2Cl2/CH3OH (or hexane/EtOAc for 22) as eluent and reversed-phase flash 
chromatography, Biotage SP1, using CH3OH/H2O as eluent to afford the final product.  
General procedure C for synthesis of (6-substituted-1,3-benzo[d]thiazol-2-yl)carbamates 24 – 26, 29, 31 
and 32: A solution of bromine (1.25 eq) in glacial acetic acid was added to a stirring mixture of an appropriate 
4-substituted aniline (1 eq), ammonium thiocyanate (4 eq), acetic acid and water at 10 °C. The reaction mixture 
was stirred at room temperature for 18 h, and then at 80 °C for 3 h. After cooling to room temperature, the 
reaction mixture was poured onto water and Na2CO3 was added in order to adjust pH to 5-6. The reaction 
mixture was extracted with ethyl acetate, layers were separated and organic layer was washed with brine. 
Organic layer was dried over anhydrous Na2SO4, filtered and evaporated to dryness. The crude product 6-
substituted benzothiazolamine was used in the next reaction step. An appropriate alkyl chloroformate (1.1 eq) 
and triethylamine (1.8 eq) were added to a solution of 6-substituted benzothiazolamine in benzene. The reaction 
mixture was stirred at 80°C for 3 h, and then poured onto cold water and extracted with ethyl acetate. Combined 
organic layers were dried over anhydrous Na2SO4, filtered and evaporated to dryness. The crude product was 
further purified in a manner provided for each compound. 
General procedure D for synthesis of compounds 28, 30 and 33 – 37: An appropriate alkyl chloroformate 
(1.1 eq) and triethylamine (1.8 eq) were added to a solution of corresponding 6-(alkylsulfanyl)-1,3-
benzothiazol-2-amine (1 eq) in benzene. After 3 h of stirring at 80 °C the reaction mixture was poured onto 
water and extracted with ethyl acetate. Combined organic layers were dried over anhydrous Na2SO4, filtered 
and evaporated to dryness. The crude product was subjected to silica gel column chromatography and silica gel 
flash chromatography, Biotage SP1, using hexane/ethyl acetate as eluent to afford the final product. 
General procedure E for synthesis of N-[6-(propylsulfanyl)-1,3-benzothiazol-2-yl]alkanamides 41 – 46: 
The alkanoyl chlorides were prepared according to known procedures using an appropriate commercially 
available acids and thionyl chloride as starting materials.2 A solution of an appropriate alkanoyl chloride (1.3 
eq) in benzene was added dropwise into the solution of corresponding benzothiazolamine (1 eq) (19 or 20) in 
CH2Cl2/benzene (1:1, v/v) at 0 °C. The reaction mixture was stirred at the same temperature until consumption 
of starting benzothiazolamine (TLC control). The reaction was quenched with cold water. The layers were 
separated and the aqueous layer was extracted with CH2Cl2. The combined organic layers were dried over 
anhydrous Na2SO4, filtered and evaporated to dryness. The crude product was subjected to a multiple column 
chromatography to afford desired compound.  
General procedure F for synthesis of compounds 27 and 38:3 
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To a stirring solution of 24 (1 eq) in CH2Cl2, MCPBA (1 eq for 38 and 4 eq for 27) was added. After stirring (4h 
in the dark for 38 and 16h for 27) at room temperature, 10% aqueous Na2S2O3 solution was added. The layers 
were separated, organic layer was washed with saturated aqueous NaHCO3 solution, dried over anhydrous 
Na2SO4, filtered and evaporated to dryness. The crude product was further purified in a manner provided for 
each compound 
General procedure G for synthesis of compounds 39 and 40:4 To a solution of 28 (1 eq) in methanol, 
acetonitrile (1.5 eq) and K2CO3 (0.7 eq) were added. The mixture is cooled to 0 °C with vigorous stirring and 
hydrogen-peroxide (1.2 eq for 39 and 4 eq for 40) was added dropwise as a solution in methanol over 30 
minutes. The reaction was maintained at 0 °C four hours (for 39) or at room temperature overnight (for 40). 
After consumption of starting material, the mixture is poured onto brine and extracted with CH2Cl2. Organic 
layers were dried over anhydrous Na2SO4 and evaporated to dryness. The crude product was further purified in 
a manner provided for each compound. 
 4-(Propyl)thioaniline (13) 
The general procedure A was followed using 1-propanethiol (471 mg, 6.18 mmol), 1-
chloro-4-nitrobenzene (650 mg, 4.12 mmol), potassium-hydroxide (694 mg, 12.4 mmol) 
and PEG-600 (19 mL) to afford 433 mg of final product as brown oil. Yield 63%. IR 
(ATR): 3456m, 3349s, 3214m, 3026m, 2961s, 2928s, 2870m, 1620s, 1596s, 1494s, 1457m, 
1377m, 1284s, 1236m, 1176m, 1146m, 1089m, 1011m, 821m, 734w, 629w, 515w cm−1. 1H NMR (500 MHz, 
CDCl3, δ): 7.23 (d, J = 8.2 Hz, 2H), 6.62 (d, J = 8.6 Hz, 2H), 2.77 – 2.71 (m, 2H), 1.63 – 1.54 (m, 2H), 0.97 (t, 
J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 145.54, 133.69, 123.78, 115.52, 38.33, 22.62, 13.22. 
4-(Butylthio)aniline (14)  
The general procedure A was followed using 1-butanethiol (204 µL, 1.904 mmol), 1-
chloro-4-nitrobenzene (200 mg, 1.27 mmol), potassium-hydroxide (214 mg, 3.81 
mmol) and PEG-1000 (6 g) to afford 111.7 mg of final product as brown oil. Yield 49%. 1H NMR (500 MHz, 
CDCl3, δ): 7.23 (d, J = 8.5 Hz, 1H), 6.62 (d, J = 8.3 Hz, 1H), 3.72 (bs, 2H), 2.77 (t, J = 7.4 Hz, 2H), 1.58 – 1.52 
(m, 2H), 1.44 – 1.36 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 145.61, 133.67, 123.92, 
115.57, 36.05, 31.49, 21.79, 13.63. 
 [4-(Isobutylthio)phenyl]amine (15)  
The general procedure A was followed using 2-methyl-1-propanthiol (516 µL, 4.75 
mmol), 1-chloro-4-nitrobenzene (500 mg, 3.17 mmol), potassium-hydroxide (534 mg, 
NH2
S
NH2
S
NH2
S
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9.52 mmol) and PEG-600 (15 mL) to afford 110.1 mg of final product as a brown oil. Yield 19%. IR (ATR): 
3462m, 3360m, 3217m, 3023m, 2956s, 2926m, 2868m, 1621s, 1598s, 1494s, 1462m, 1282m, 1245m, 1175m, 
822m cm−1. 1H NMR (500 MHz, CDCl3, δ): 7.22 (d, J = 8.7 Hz, 2H), 6.61 (d, J = 8.5 Hz, 2H), 3.67 (bs, 2H), 
2.66 (d, J = 6.9 Hz, 2H), 1.76 (sep, J = 6.8 Hz, 1H), 0.99 (d, J = 6.6 Hz, 6H). 13C NMR (125 MHz, CDCl3, δ): 
145.54, 133.47, 124.42, 115. 56, 45.52, 28.18, 21.89. (+)ESI-HRMS: m/z 182.09943 corresponds to molecular 
formula C10H15NSH+ (error, -2.02 ppm). 
4-(Pentylthio)aniline (16)  
The general procedure A was followed using 1-pentanethiol (472 µL, 3.80 mmol), 1-
chloro-4-nitrobenzene (400 mg, 2.54 mmol), potassium-hydroxide (428 mg, 7.63 
mmol) and PEG-600 (12 mL) to afford 156 mg of final product as yellow oil. Yield 31%. IR (ATR): 3459m, 
3362s, 3213m, 3026m, 2956s, 2927s, 2857s, 1621s, 1597s, 1495s, 1462m, 1378w, 1336m, 1283s, 1177m, 
1111w, 1094w, 822m, 518m cm−1. 1H NMR (500 MHz, CDCl3, δ): 7.22 (d, J = 8.6 Hz, 2H), 6.62 (d, J = 8.2 Hz, 
2H), 3.72 (bs, 2H), 2.76 (t, J = 7.5 Hz, 2H), 1.59 – 1.53 (m, 2H), 1.39 – 1.26 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H). 
13C NMR (125 MHz, CDCl3, δ): 145.62, 133.65, 123.91, 115.56, 36.34, 30.86, 29.06, 22.24, 13.95. (+)ESI-
HRMS: m/z 196.11548 corresponds to molecular formula C11H17NSH+ (error, +0.15 ppm). 
6-(Propylsulfanyl)-1,3-benzothiazol-2-amine (19)  
The general procedure B was followed using solution of bromine (215 µL, 4.20 
mmol) in acetic acid (1.4 mL), 4-(propylthio)aniline (562.7 mg, 3.364 mmol), 
ammonium thiocyanate (1.02 g, 13.4 mmol), acetic acid (5.6 mL) and water (0.3 mL) to afford 617.2 mg of 
final product as pale yellow solid. Yield 82%. M.p. = (115 – 117) °C. IR (ATR): 3369s, 3290m, 3092s, 2962s, 
2924s, 2863m, 2753m, 1641s, 1589m, 1532s, 1445s, 1300m, 1268m, 1117m, 1001w, 894w, 876w, 810m cm−1. 
1H NMR (500 MHz, CDCl3, δ): 7.60 (d, J = 1.8 Hz, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.35 (dd, J1 = 8.5 Hz, J2 = 
1.8 Hz, 1H), 2.87 (t, J = 7.3 Hz, 2H), 1.68 – 1.60 (m, 2H), 1.01 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, 
(CD3)2SO, δ): 166.69, 151.66, 131.89, 128.24, 126.78, 122.76, 117.93, 36.32, 22.04, 13.04. (+)ESI-HRMS: m/z 
225.05194 corresponds to molecular formula C10H12N2S2H+ (error, +2.10 ppm). 
6-(Butylsulfanyl)-1,3-benzothiazol-2-amine (20)  
The general procedure B was followed using solution of bromine (209 µL, 4.08 
mmol) in acetic acid (2.1 mL), 4-(butylthio)aniline 14 (593 mg, 3.27 mmol), 
ammonium thiocyanate (995.6 mg, 13.08 mmol), acetic acid (8.5 mL) and water (0.45 mL) to afford 725 mg of 
final product as pale yellow solid. Yield 93%. M.p. = (96 – 98) °C. IR (ATR): 3397s, 3277m, 3084m, 2962s, 
2928s, 2871m, 2736w, 1635s, 1591m, 1529s, 1453s, 1299m, 1271m, 1110m, 809m, 766w cm−1. 1H NMR (500 
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MHz, CDCl3, δ): 7.61 (d, J = 1.8 Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.34 (dd, J1 = 8.3 Hz, J2 = 1.8 Hz, 1H), 5.21 
(bs, 2H), 2.89 (t, J = 7.3 Hz, 2H), 1.63 – 1.57 (m, 2H), 1.47 – 1.40 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H). 13C NMR 
(125 MHz, CDCl3, δ): 165.77, 150.85, 132.32, 129.71, 129.18, 123.12, 119.36, 35.27, 31.35, 21.84, 13.61. 
(+)ESI-HRMS: m/z 239.06740 corresponds to molecular formula C11H14N2S2H+ (error, +1.18 ppm). 
6-(Isobutylthio)-1,3-benzothiazol-2-amine (21)  
The general procedure B was followed using solution of bromine (36 µL, 0.70 mmol) 
in acetic acid (0.4 mL), 4-(isobutylthio)aniline 15 (83 mg, 0.56 mmol), ammonium 
thiocyanate (170.3 mg, 2.237 mmol), acetic acid (1.5 mL) and water (70 µL) to afford 
72.2 mg of final product as yellow solid. Yield 54%. M.p. = (129 – 131) °C. IR (ATR): 3354m, 3290m, 3234m, 
3080s, 2959s, 2748w, 1642s, 1588w, 1526s, 1440s, 1365w, 1332w, 1301m, 1269m, 1114m, 821m cm−1. 1H 
NMR (500 MHz, CDCl3, δ): 7.61 (bs, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.3 – 7.32 (m, 1H), 5.47 (bs, 2H), 2.78 (d, J 
= 6.9 Hz, 2H), 1.82 (sep, J = 6.7 Hz, 1H), 1.02 (d, J = 6.6 Hz, 6H). 13C NMR (125 MHz, CDCl3, δ): 165.83, 
150.80, 132.31, 130.16, 129.10, 123.02, 119.35, 44.68, 28.24, 21.94. (+)ESI-HRMS m/z 239.06666 corresponds 
to molecular formula C11H14N2S2H+ (error, -1.89 ppm). 
6-(Pentylsulfanyl)-1,3-benzothiazol-2-amine (22) 
The general procedure B was followed using solution of bromine (42 µL, 0.82 
mmol) in acetic acid (0.5 mL), 4-(pentylthio)aniline 16 (129 mg, 0.660 mmol), 
ammonium thiocyanate (201 mg, 2.64 mmol), acetic acid (2 mL) and water (0.1 mL) to afford 68.8 mg of final 
product as  yellow oil. Yield 56%. IR (ATR): 3429m, 3279m, 3075s, 2957s, 2927s, 2859s, 2730m, 1643s, 
1588m, 1526s, 1452s, 1372m, 1338m, 1319m, 1298m, 1271m, 1106m, 1045w, 894w, 814m cm-1. 1H NMR 
(500 MHz, CDCl3, δ): 7.61 (d, J = 1.8 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.33 (dd, J1 = 8.2 Hz, J2 = 1.8 Hz, 1H), 
5.46 (s, 2H), 2.89 – 2.86 (m, 2H), 1.64 – 1.58 (m, 2H), 1.42 – 1.28 (m, 4H), 0.88 (t, J = 7.2 Hz, 3H). 13C NMR 
(125 MHz, CDCl3, δ): 165.85, 150.89, 132.32, 129.70, 129.17, 123.11, 119.35, 35.57, 30.88, 28.95, 22.21, 
13.93. (+)ESI-HRMS: m/z 235.08255 corresponds to molecular formula C12H16N2S2H+ (error, -0.85 ppm). 
Ethyl [6-(ethylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (24)  
The general procedure C was followed using a solution of bromine (101 µL, 1.97 
mmol) in glacial acetic acid (1 mL), 4-(ethylthio)aniline hydrochloride (300 mg, 
1.58 mmol), ammonium thiocyanate (481 mg, 6.32 mmol), glacial acetic acid (4 
mL) and water (0.15 mL). The crude product was dissolved in benzene (5 mL) and subjected to the next 
reaction step including ethyl chloroformate (165 µL, 1.73 mmol) and triethylamine (395 µL, 2.83 mmol). 179.4 
mg of the final product was obtained after crystallization from benzene as pale yellow solid. Yield 40%. M.p. = 
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(162 – 165) °C. IR (ATR): 3432w, 3400w, 3162m, 3124m, 3079m, 3045m, 2973s, 2924s, 2776m, 1720s, 
1599s, 1557s, 1444s, 1364m, 1290s, 1250s, 1119m, 1070m, 1048m, 1021w, 820m, 757m cm−1. 1H NMR (500 
MHz, (CD3)2SO, δ): 7.96 (d, J = 1.6 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.36 (dd, J1 = 8.4 Hz, J2 = 1.8 Hz, 1H), 
4.24 (q,  J = 7.1 Hz, 2H), 2.98 (q, J = 7.3 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H), 1.22 (t, J = 7.3 Hz, 3H). 13C NMR 
(125 MHz, (CD3)2SO, δ): 159.53, 153.88, 147.84; 132.61, 130.26, 127.58, 121.85, 120.52, 61.94, 27.48, 14.30. 
(+)ESI-HRMS: m/z 283.05655 corresponds to molecular formula C12H14N2O2S2H+ (error, -1.38 ppm). HPLC 
purity, method A: tR = 8.695, area 99.27%. Method B: tR = 9.906, area 96.29%. 
Ethyl [6-(propylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (25)  
The general procedure C was followed using a solution of bromine (63 µL, 1.2 
mmol) in glacial acetic acid (0.5 mL), 4-(propylthio)aniline hydrochloride (200 
mg, 0.982 mmol), ammonium thiocyanate (299 mg, 3.93 mmol), glacial acetic 
acid (2.5 mL) and water (0.1 mL). The crude product was dissolved in benzene (5 mL) and subjected to the next 
reaction step including ethyl chloroformate (103 µL, 1.08 mmol) and triethylamine (246 µL, 1.76 mmol). The 
crude product was subjected to silica gel column chromatography using hexane/ethyl acetate as eluent, to afford 
60 mg of final product as pale yellow solid. Yield 21%. M.p. = (158 – 162) °C. IR (ATR): 3135w, 3076w, 
2957m, 2909m, 2869m, 2782m, 1725s, 1597s, 1561s, 1453s, 1428m, 1270s, 1243s, 1110m, 1069m, 1045m, 
1022m, 816m, 759m, 707m cm−1. 1H NMR (500 MHz, (CD3)2SO, δ): 12.00 (bs, 1H), 7.96 (d, J = 1.4 Hz, 1H), 
7.60 (d, J = 8.5 Hz, 1 H), 7.36 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 2.94 (t, J = 7.1 Hz, 
2H), 1.61 – 1.54 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 0.96 (t, J = 7.3 Hz, 3H). 13C NMR (50 MHz, (CD3)2SO, δ): 
159.85, 154.23, 148.00, 132.89, 130.76, 127.84, 122.09, 120.78, 62.20, 35.57, 22.22, 14.52, 13.34. (+)ESI-
HRMS: m/z 297.07191 corresponds to molecular formula C13H16N2O2S2H+ (error, -2.30 ppm). HPLC purity, 
method A: tR = 9.194, area 99.67%. Method B: tR = 10.528, area 99.44%. 
Propyl (6-ethoxy-1,3-benzothiazol-2-yl)carbamate (26) 
The general procedure C was followed using a solution of bromine (93 µL, 1.8 
mmol) in glacial acetic acid (0.5 mL), 4-ethoxyaniline (188 µL, 1.46 mmol), 
ammonium thiocyanate (444 mg, 5.83 mmol), glacial acetic acid (2.5 mL) and 
water (0.1 mL). The crude product was dissolved in benzene (5 mL) and subjected to the next reaction step 
including propyl chloroformate (180 µL, 1.6 mmol) and triethylamine (366 µL, 2.63 mmol). The crude product 
was subjected to silica gel column chromatography using hexane/ethyl acetate as eluent. After the 
crystallization from benzene 100.7 mg of final product was obtained as pale yellow solid. Yield 25%. M.p. = 
(168 – 169) °C. IR (ATR): 3161w, 3081m, 2977s, 2933m, 2802m, 1718s, 1612s, 1562s, 1463s, 1391m, 1272s, 
1242s, 1212s, 1113m, 1057s, 971w, 941m, 792m, 760m cm−1. 1H NMR (500 MHz, (CD3)2SO, δ): 11.83 (bs, 
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1H), 7.56 (d, J = 8.9 Hz, 1H), 7.51 (d, J = 2.5 Hz, 1H), 6.97 (dd,  J1 = 8.7 Hz, J2 = 2.5 Hz, 1H), 4.14 (t, J = 6.6 
Hz, 1H), 4.04 (q, J = 7.0 Hz, 2H), 1.69 – 1.62 (m, 2H), 1.33 (t, J = 6.9 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H). 13C 
NMR (125 MHz, (CD3)2SO, δ): 157.46, 155.12, 143.28, 132.76, 120.81, 114.97, 105.47, 67.16, 63.62, 21.73, 
14.70, 10.13. (+)ESI-HRMS: m/z 281.09541 corresponds to molecular formula C13H16N2O3SH+ (error, -0.10 
ppm). HPLC purity, method A: tR = 8.520, area 99.48%. Method B: tR = 9.741, area 96.69%. 
Ethyl [6-(ethanesulfonyl)-1,3-benzothiazol-2-yl]carbamate (27) 
The general procedure F was followed using 24 (50 mg, 0.2 mmol), CH2Cl2 (15 
mL) and MCPBA (122 mg, 0.707 mmol). The 30.5 mg of final product was 
obtained as pale yellow solid. Yield 55%. M.p. = (257 – 259) °C. IR: 3121m, 
3072w, 2979m, 2944m, 2775w, 1721s, 1602m, 1556s, 1450m, 1307s, 1254m, 
1150s, 1103w, 1044w, 1018w, 830w, 786w, 757w, 715w cm−1. 1H NMR (500 MHz, (CD3)2SO, δ): 12.37 (bs, 
1H), 8.58 (d, J = 0.9 Hz, 1H), 7.89 – 7.85 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.31 – 3.28 (m, 2H), 1.30 (t, J = 7.1 
Hz, 3H), 1.12 (t, J = 7.5 Hz, 3 H). 13C NMR (125 MHz, CDCl3, (CD3)2SO, δ): 163.77, 153.80, 152.94, 132.42, 
132.16, 125.29, 122.37, 120.27, 62.05, 49.76, 14.12, 7.18. (+)ESI-HRMS: m/z 315.04662 corresponds to 
molecular formula C12H14N2O4S2H+ (error, -0.48 ppm). HPLC purity, method D: tR = 4.187, area 95.46%. 
Method I: tR = 4.662, area 95.51%. 
Propyl [6-(propylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (28) 
The general procedure D was followed using propyl chloroformate (854 µL, 
7.60 mmol), triethylamine (1.75 mL, 12.4 mmol), 19 (1.55 g, 6.91 mmol) and 
benzene (18 mL). The final product was obtained as pale yellow solid. The 
yield was 778 mg (47%). M.p. = (138 – 140) °C. IR (ATR): 3167m, 3062m, 
2960s, 2932m, 2876m, 1724s, 1598s, 1562s, 1449m, 1447s, 1308m, 1273s, 1244s, 1047m, 962w, 888w, 805m, 
782m, 755m cm−1. 1H NMR (500 MHz, (CD3)2SO, δ): 12.01 (bs, 1H), 7.96 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 8.4 
Hz, 1H), 7.36 (dd, J1 = 8.4 Hz, J2 = 1.9 Hz, 1H), 4.15 (t, J = 6.7 Hz, 2H), 2.94 (t, J = 7.2 Hz, 2H), 1.70  ̶  1.63 
(m, 2H), 1.61 – 1.54 (m, 2H), 0.98 – 0.92 (m, 6H). 13C NMR (125 MHz, (CD3)2SO, δ): 159.54, 154.00, 147.74, 
132.61, 130.49, 127.58, 121.82, 120.49, 67.28, 35.38, 21.99, 21.68, 13.09, 10.10. (+)ESI-HRMS: m/z 
311.08810 corresponds to molecular formula C14H18N2O2S2H+ (error, -0.47 ppm). HPLC purity, method A: tR = 
11.532, area 98.23%. Method B: tR = 13.159, area 98.53%. 
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Ethyl [6-(butylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (29) 
The general procedure C was followed using a solution of bromine (90 µL, 
1.8 mmol) in glacial acetic acid (1 mL), 4-(butylthio)aniline (14) (253.9 mg, 
1.400 mmol), ammonium thiocyanate (426 mg, 5.60 mmol), glacial acetic 
acid (4 mL) and water (0.15 mL). The crude product was dissolved in benzene (5 mL) and subjected to the next 
reaction step including ethyl chloroformate (147 µL, 1.54 mmol) and triethylamine (351 µL, 2.52 mmol). The 
crude product was subjected to silica gel column chromatography using hexane/ethyl acetate as eluent. The final 
product was obtained after crystallization from benzene as 83.2 mg of pale yellow solid. Yield 19%. M.p. = 
(138 – 140) °C. IR (ATR): 3139m, 3072s, 2983s, 2954s, 2931s, 2865s, 2794s, 1724s, 1603s, 1570s, 1452s, 
1366m, 1340m, 1313m, 1293s, 1274s, 1250s, 1113m, 1070m, 1048m, 1022m, 816s, 781m, 760s, 708m cm−1. 
1H NMR (500 MHz, CDCl3, δ): 11.90 (bs, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H), 7.40 (dd, J1 = 
8.4 Hz, J2 = 1.8 Hz, 1H), 4.41 (q, J = 7.3 Hz, 2H), 2.96 (t, J = 7.5 Hz, 2H), 1.67 – 1.61 (m, 2H), 1.50 – 1.41 (m, 
5H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, (CD3)2SO, δ): 161.39, 153.81, 147.21, 132.40, 131.82, 
128.33, 122.21, 120.81, 62.88, 34.73, 31.28, 21.89, 14.46, 13.63. (+)ESI-HRMS: m/z 311.08801 corresponds to 
molecular formula C14H18N2O2S2H+ (error, -0.76 ppm). HPLC purity, method A: tR = 9.757, area 97.08%. 
Method B: tR = 11.594, area 96.14%. 
Propyl [6-(butylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (30)  
The general procedure D was followed using propyl chloroformate (713 
µL, 6.34 mmol), triethylamine (1.45 mL, 10.4 mmol), 20 (1.37 g, 5.77 
mmol) and benzene (29 mL). The final product was obtained as yellow 
solid. The yield was 543 mg (29%). M.p. = 130 °C. IR (ATR): 3169m, 3068m, 2960s, 2926s, 2785m, 1725s, 
1601m, 1564m, 1451m, 1288m, 1247m, 1070w, 818w, 752w cm−1. 1H NMR (500 MHz, CDCl3, δ): 11.35 (bs, 
1H), 7.82 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 1.4 Hz, 1H), 7.40 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 4.30 (t, J = 6.8 
Hz, 2H), 2.96 (t, J = 7.4 Hz, 2H), 1.84  ̶  1.77 (m, 2H), 1.67 – 1.61 (m, 2H), 1.50 – 1.42 (m, 2H), 0.99 (t, J = 7.5 
Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 161.06, 153.80, 147.35, 132.54, 131.83, 
128.42, 122.29, 120.83, 68.53, 34.77, 31.31, 22.14, 21.91, 13.65, 10.32. (+)ESI-HRMS: m/z 325.10408 
corresponds to molecular formula C15H20N2O2S2H+ (error, +0.56 ppm). HPLC purity, method A: tR = 10.371, 
area 96.76%. Method B: tR = 12.388, area 98.58%. 
Butyl [6-(propylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (31)  
The general procedure C was followed using a solution of bromine (94 µL, 
1.8 mmol) in glacial acetic acid (1 mL), 4-(propylthio)aniline 
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hydrochloride (300 mg, 1.47 mmol), ammonium thiocyanate (448 mg, 5.88 mmol), glacial acetic acid (4 mL) 
and water (0.15mL). The crude product was dissolved in benzene (5 mL) and subjected to the next reaction step 
including butyl chloroformate (205 µL, 1.61 mmol) and triethylamine (369 µL, 2.65 mmol). The crude product 
was subjected to silica gel column chromatography using hexane/ethyl acetate as eluent and then crystallized 
from benzene as pale yellow solid. The yield was 133 mg, 28%. M.p. = (74 – 80) °C. IR (ATR): 3170m, 
3070m, 2961s, 2931s, 2872m, 1721s, 1602s, 1562s, 1456m, 1293s, 1248s, 1074w, 814w, 762wcm−1. 1H NMR 
(500 MHz, (CD3)2SO, δ): 7.94 (d, J = 1.6 Hz, 1H), 7.60 (d, J = 8.3 Hz, 1H), 7.35 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 
1H), 4.19 (t, J = 6.6 Hz, 2H), 2.94 (t, J = 7.1 Hz, 2H), 1.65 – 1.53 (m, 4H), 1.41 – 1.35 (m, 2H), 0.95 (t, J = 7.3 
Hz, 3H), 0.91 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, (CD3)2SO, δ): 159.60, 154.04, 147.74, 132.63, 130.53, 
127.60, 121.84, 120.51, 65.59, 35.43, 30.34, 22.02, 18.50, 13.55, 13.11. (+)ESI-HRMS: m/z 325.10391 
corresponds to molecular formula C15H20N2O2S2H+ (error, +0.05 ppm).  HPLC purity, method A: tR = 10.346, 
area 99.78%. Method B: tR = 11.916, area 99.36%. 
Propyl [6-(ethylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (32)  
The general procedure C was followed using a solution of bromine (101 µL, 1.80 
mmol) in glacial acetic acid (1 mL), 4-(propylthio)aniline hydrochloride (300 mg, 
1.58 mmol), ammonium thiocyanate (481 mg, 6.32 mmol), glacial acetic acid (4 
mL) and water (0.15mL). The crude product was dissolved in benzene (7 mL) and subjected to the next reaction 
step including propyl chloroformate (195 µL, 1.73 mmol) and triethylamine (396 µL, 2.84 mmol). The crude 
product was subjected to silica gel column chromatography using hexane/ethyl acetate as eluent and reversed-
phase flash chromatography, Biotage SP1, using CH3OH/H2O as eluent to afford 125 mg of final product as 
pale yellow solid. Yield 27%. M.p. = (137 – 138) °C. IR (ATR): 3062m, 2968s, 2922s, 1717s, 1600m, 1562m, 
1445m, 1396w, 1287m, 1248m, 1072w, 1044w, 759w, cm−1. 1H NMR (500 MHz, (CD3)2SO, δ): 12.01 (bs, 1H), 
7.95 (d, J = 1.8 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.36 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 4.15 (t, J = 6.8 Hz, 
1H), 2.98 (q, J = 7.3 Hz, 2H), 1.70 – 1.63 (m, 2H), 1.22 (t,  J = 7.3 Hz, 3H), 0.93 (t, J = 7.5 Hz, 3H). 13C NMR 
(125 MHz, (CD3)2SO, δ): 160.13, 154.54, 148.24, 133.06, 130.67, 128.02, 122.27, 120.93, 67.73, 27.93, 22.12, 
14.74, 10.56. (+)ESI-HRMS: m/z 297.07243 corresponds to molecular formula C13H16N2O2S2H+ (error, -0.57 
ppm). HPLC purity, method B: tR = 12.996, area 95.61%. Method C: tR = 14.178, area 95.09%. 
Ethyl [6-(pentylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (33)  
The general procedure D was followed using ethyl chloroformate (78 µL, 
0.82 mmol), triethylamine (186 µL, 1.33 mmol), 22 (188 mg, 0.745 mmol) 
and benzene (4 mL). The final product was obtained as pale yellow solid. 
The yield was 51.4 mg (21%). M.p. = (137 – 138) °C. IR (ATR): 3175m, 3152m, 3123m, 3058m, 2956s, 2924s, 
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2854s, 1724s, 1597s, 1550s, 1460s, 1370m, 1296s, 1241s, 1069m, 818m, 766m cm−1. 1H NMR (500 MHz, 
CDCl3, δ): 11.60 (bs, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 1.6 Hz, 1H), 7.40 (dd, , J1 = 8.5 Hz, J2 = 1.6 Hz, 
1H), 4.40 (q, J = 7.1 Hz, 2H), 2.95 (t, J = 7.5 Hz, 2H), 1.69 – 1.63 (m, 2H), 1.45 – 1.39 (m, 5H), 1.37 – 1.29 (m, 
2H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 161.19, 153.75, 147.25, 132.47, 131.85, 128.37, 
122.22, 120.82, 62.90, 35.01, 30.93, 28.88, 22.23, 14.46, 13.94. (+)ESI-HRMS: m/z 325.10435 corresponds to 
molecular formula C15H20N2O2S2H+ (error, +1.40 ppm). HPLC purity, method A: tR =12.206, area 98.52%. 
Method D: tR = 4.563, area 98.28%. 
Propyl [6-(pentylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (34)  
The general procedure D was followed using propyl chloroformate (92 µL, 
0.82 mmol), triethylamine (186 µL, 1.33 mmol), 22 (188 mg, 0.745 mmol) 
and benzene (4 mL). The final product was obtained as yellow solid. The 
yield was 101.4 mg (40%). M.p. = (116 – 118) °C. IR (ATR): 3170m, 3127m, 3062m, 2956s, 2923s, 2853s, 
2784m, 1725s, 1601s, 1562s, 1451m, 1393m, 1309m, 1289s, 1248s, 1069m, 821m, 752m cm−1. 1H NMR (500 
MHz, CDCl3, δ): 11.72 (bs, 1H), 7.84 (d, J = 8.6 Hz, 1H), 7.78 (d, J = 1.5 Hz, 1H), 7.40 (dd, J1 = 8.4 Hz, J2 = 
1.8 Hz, 1H), 4.30 (t, J = 6.8 Hz, 2H), 2.94 (t, J = 7.4 Hz, 2H), 1.84 – 1.77 (m, 2H), 1.69 – 1.63 (m, 2H), 1.45 – 
1.39 (m, 2H), 1.36 – 1.29 (m, 2H), 0.99 (t, J = 7.5 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, 
CDCl3, δ): 161.31, 153.88, 147.26, 132.43, 131.80, 128.37, 122.23, 120.77, 68.50, 35.03, 30.92, 28.87, 22.22, 
22.11, 13.93, 10.30. (+)ESI-HRMS: m/z 339.12006 corresponds to molecular formula C16H22N2O2S2H+ (error, 
+1.51 ppm). HPLC purity, method A: tR = 13.079, area 96.82%. Method B: tR = 14.812, area 95.51%. 
Ethyl {6-[(2-methylpropyl)sulfanyl]-1,3-benzothiazol-2-yl}carbamate (35) 
The general procedure D was followed using ethyl chloroformate (34 µL, 0.36 
mmol), triethylamine (82 µL, 0.58 mmol), 21 (77 mg, 0.32 mmol) and 
benzene (1.8 mL) to afford 19.1 mg of final product as white solid. Yield 23%. 
M.p. = (159 – 160) °C. IR (ATR): 3139m, 3081m, 2968s, 2914s, 2866m, 1722s, 1599s, 1560s, 1458m, 1275s, 
1246s, 1111m, 1070m, 1049m, 1019m, 820m, 789m, 762m cm−1. 1H NMR (500 MHz, CDCl3, δ): 11.47 (bs, 
1H), 7.84 (d, J = 8.5 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.40 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 4.41 (q, J = 7.1 
Hz, 2H), 2.85 (d, J = 6.9 Hz, 2H), 1.88 (sep, J = 6.7 Hz, 1H), 1.42 (t, J = 7.1 Hz, 3H), 1.05 (d, J = 6.6 Hz, 6H). 
13C NMR (125 MHz, CDCl3, δ): 161.25, 153.77, 147.18, 132.44, 132.27, 128.30, 122.13, 62.88, 44.10, 28.32, 
22.01, 14.46. (+)ESI-HRMS: m/z 311.08796 corresponds to molecular formula C14H18N2O2S2H+ (error, -0.92 
ppm). HPLC purity, method E: tR = 12.189, area 99.00%. Method B: tR = 13.873, area 99.59%. 
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 Propyl {6-[(2-methylpropyl)sulfanyl]-1,3-benzothiazol-2-yl}carbamate (36)  
The general procedure D was followed using propyl chloroformate (33 µL, 
0.29 mmol), triethylamine (67 µL, 0.29 mmol), 21 (63.9 mg, 0.268 mmol) and 
benzene (1.5 mL) to afford 53.7 mg of final product as pale yellow solid. 
Yield 62%. M.p. = (139 – 141) °C. IR (ATR): 3172m, 3131m, 3074m, 2919s, 
2852m, 1722s, 1599m, 1565m, 1456m, 1282s, 1245s, 1074m, 818m, 760m cm−1. 1H NMR (500 MHz, CDCl3, 
δ): 11.60 – 11.58 (m, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.40 (dd, J1 = 8.4 Hz, J2 = 1.8 Hz, 
1H), 4.30 (t, J = 6.8 Hz, 2H), 2.85 (d, J = 6.8 Hz, 2H), 1.91 – 1.77 (m, 3H), 1.05 (d, J = 6.6 Hz, 6H), 0.99 (t, J = 
7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 161.18, 153.85, 147.23, 132.47, 132.25, 128.33, 122.16, 120.79, 
68.49, 44.11, 28.31, 22.00, 10.30. (+)ESI-HRMS: m/z325.10387 corresponds to formula C15H20N2O2S2H+ 
(error, -0.08 ppm). HPLC purity, method E: tR = 12.787, area 98.08%. Method F: tR = 14.618, area 99.74%. 
Butyl [6-(butylsulfanyl)-1,3-benzothiazol-2-yl]carbamate (37)  
The general procedure D was followed using butyl chloroformate (175 
µL, 1.35 mmol), triethylamine (309 µL, 2.21 mmol), 20 (293.7 mg, 1.232 
mmol) and benzene (5 mL) to afford 131 mg of final product as yellow 
solid. Yield 32%. M.p. = (120 – 121) °C. IR (ATR): 3143m, 3077m, 
2953s, 2928s, 2866m, 1727s, 1598s, 1452m, 1276m, 1246m, 1108w, 1074w, 820m, 782w, 756m cm−1. 1H 
NMR (500 MHz, CDCl3, δ): 11.64 – 11.41 (m, 1H), 7.84 – 7.81 (m, 1H), 7.78 (d, J = 1.5 Hz, 1H), 7.40 (dd, J1 = 
8.6 Hz, J2 = 1.7 Hz, 1H), 4.35 (t, J = 6.7 Hz, 2H), 2.96 (t, J = 7.4 Hz, 2H), 1.79 – 1.73 (m, 2H), 1.67 – 1.61 (m, 
2H), 1.50 – 1. 38 (m, 4H), 0.97 – 0.91 (m, 6H). 13C NMR (125 MHz, CDCl3, δ): 161.50, 153.95, 147.22, 
132.39, 131.77, 128.33, 122.25, 120.76, 66.76, 34.75, 31.28, 30.76, 21.88, 18.99, 13.66. (+)ESI-HRMS: m/z 
339.12048 corresponds to molecular formula C16H22N2O2S2H+ (error, +2.77 ppm). HPLC purity, method E: tR = 
12.749, area 95.92%. Method F: tR =14.577, area 98.25%. 
Ethyl [6-(ethanesulfinyl)-1,3-benzothiazol-2-yl]carbamate (38)  
The general procedure F was followed using 24 (42.5 mg, 0.151 mmol), CH2Cl2 
(20 mL) and MCPBA (26.0 mg, 0.151 mmol). Na2SO4, The crude product was 
purified by reversed-phase flash chromatography, Biotage SP1, using 
CH3OH/H2O as eluent affording 12.6 mg of white solid. Yield 28%. M.p. = 195 °C. IR (ATR): 3359m, 3175m, 
3056m, 2924s, 2853s, 1713s, 1658m, 1634m, 1602s, 1564s, 1448m, 1366m, 1301s, 1276m, 1250s, 1103m, 
1072m, 1044m, 891w, 827w, 794m, 761m, 708w cm−1. 1H NMR (500 MHz, CDCl3, δ): 10.94 (bs, 1H), 8.13 (d, 
J = 1.4 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.59 (dd, J1= 8.5 Hz, J2 = 1.6 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.00 – 
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2.93 (m, 1H), 2.88 – 2.81 (m, 1H), 1.43 (t, J = 7.2 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, 
CDCl3, δ): 163.04, 153.58, 150.90, 138.24, 132.77, 121.84, 121.18, 117.98, 63.26, 50.76, 14.47, 6.14. (+)ESI-
HRMS: m/z 299.05162 corresponds to molecular formula C12H14N2O3S2H+ (error, -0.81 ppm). HPLC purity, 
method D: tR = 4.087, area 95.52%. Method I: tR = 4.668, area 95.14%. 
Propyl [6-(propane-1-sulfinyl)-1,3-benzothiazol-2-yl]carbamate (39)  
The general procedure G was followed using 28 (30.3 mg, 0.098 mmol), 
methanol (0.5 mL), acetonitrile (8 µL, 0.1 mmol), K2CO3 (10 mg, 0.07 mmol) 
and solution of hydrogen-peroxide (12 µL, 0.12 eq) in methanol (0.5 mL). The 
crude product was subjected to silica gel column chromatography using 
hexane/ethyl acetate as eluent to afford 8.4 mg of final product as white solid. Yield 26%. IR (ATR): 3165m, 
3127m, 3057m, 2964s, 2933s, 2876s, 2780m, 1724s, 1601s, 1557s, 1449s, 1404m, 1292s, 1274s, 1249s, 1066s, 
1032m, 966m, 890m, 829m, 784m, 754m, 708w cm−1. 1H NMR (500 MHz, CD3OD, δ): 12.21 (bs, N-H), 8.28 – 
8.26 (m, 1H), 7.84 – 7.83 (m, 1H), 7.66 – 7.64 (m, 1H), 4.17 (t, J = 6.6 Hz, 2H), 2.95 – 2.77 (m, 2H), 1.70 – 
1.47 (m, 4H), 0.97 – 0.92 (m, 6H). 13C NMR (125 MHz, CD3OD, δ): 161.76, 154.08, 151.19, 138.54, 132.39, 
121.86, 120.73, 118.13, 67.47, 57.75, 21.63, 15.32, 12.91, 10.09. (+)ESI-HRMS: m/z 327.08293 correspond to 
molecular formula C14H18N2O3S2H+ (error, -0.72 ppm). HPLC purity, method G: tR = 5.365, area 97.49%. 
Method H: tR = 3.559, area 96.03%.  
Propyl [6-(propane-1-sulfonyl)-1,3-benzothiazol-2-yl]carbamate (40) 
The general procedure G was followed using 28 (42.2 mg, 0.136 mmol), 
methanol (0.5 mL), acetonitrile (10 µL, 0.2 mmol), K2CO3 (13 mg, 0.095 mmol) 
and solution of hydrogen-peroxide (54 µL, 0.54 mmol) in methanol (0.5 mL). 
The crude product was subjected to silica gel column chromatography using 
hexane/ethyl acetate as an eluent and reversed-phase flash chromatography using CH3OH/H2O as an eluent to 
afford 22.5 mg of final product as white solid. Yield 48%. M.p. = 270 °C. IR (ATR): 3169m, 3125m, 2971s, 
2936m, 2880m, 2771w, 1730s, 1598m, 1550s, 1454m, 1405w, 1346w, 1306s, 1279s, 1231s, 1147s, 1103m, 
1072m, 942w, 825w, 784m, 757m, 710wcm−1. 1H NMR (500 MHz, CD3OD, δ): 12.37 (bs, N-H), 8.57 – 8.56 
(m, 2H), 7.88 – 7.84 (m, 2H), 4.18 (t, J = 6.6 Hz, 2H), 3.30 – 3.26 (m, 2H), 1.72 – 1.66 (m, 2H), 1.60 – 1.53 (m, 
2H), 0.96 – 0.89 (m, 6H). 13C NMR (125 MHz, CD3OD, δ): 164.40, 154.55, 153.40, 133.75, 132.65, 125.91, 
123.03, 120.99, 68.09, 57.20, 22.11, 16.76, 12.99, 10.57. (+)ESI-HRMS: m/z 343.07768 corresponds to 
molecular formula C14H18N2O4S2H+ (error, -1.16 ppm). HPLC purity, method G: tR = 5.253, area 98.21%. 
Method I: tR = 5.480, area 97.67%. 
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N-[6-(propylsulfanyl)-1,3-benzothiazol-2-yl]pentanamide (41) 
The general procedure E was followed using a solution of pentanoyl 
chloride (87.2 mg, 0.723 mmol) in benzene (1.5 mL) and a solution of 19 
(124.8 mg, 0.556 mmol) in CH2Cl2/benzene (2 mL, 1:1, v/v). The reaction 
mixture was stirred for 4 h and worked up according to general procedure. The crude product was subjected to 
silica gel column chromatography using hexane/ethyl acetate and reversed-phase flash chromatography, Biotage 
SP1, using methanol/water as eluent to afford 35.3 mg of final product as pale yellow solid. Yield 21%. M.p. = 
113 °C. IR (ATR): 3276m, 3178m, 3128m, 3064m, 2960s, 2930m, 2870m, 1660s, 1594s, 1538s, 1439m, 
1374w, 1345m, 1295m, 1266m, 1192w, 1087w, 815w, 774w cm−1. 1H NMR (500 MHz, CDCl3, δ): 10.66 (bs, 
1H), 7.81 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.44 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 2.94 (t, J = 7.3 
Hz, 2H), 2.46 (t, J = 7.6 Hz, 2H), 1.73  ̶  1.66 (m, 4H), 1.37  ̶  1.30 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 
7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 171.64, 158.91, 146.43, 132.89, 132.38, 128.68, 122.46, 120.58, 
36.91, 36.26, 26.97, 22.54, 22.19, 13.64, 13.38. (+)ESI-HRMS: m/z 309.10813 corresponds to molecular 
formula C15H20N2OS2H+ (error, -2.76 ppm). HPLC purity, method A: tR = 11.671, area 97.05%. Method B: tR = 
13.245, area 98.01%.  
N-[6-(butylsulfanyl)-1,3-benzothiazol-2-yl]pentanamide (42) 
The general procedure E was followed using a solution of pentanoyl chloride 
(69.6 mg, 0.58 mmol) in benzene (1 mL) and a solution of 20 (86 mg, 0.36 
mmol) in CH2Cl2/benzene (2.2 mL, 1:1, v/v). The reaction mixture was stirred 
for 3 h at 0°C, then 13 h at room temperature and worked up according to general procedure. The crude product 
was subjected to silica gel column chromatography using hexane/ethyl acetate and reversed-phase flash 
chromatography, Biotage SP1, using methanol/water as eluent to afford 32.6 mg of final product as white solid. 
Yield 28%. M.p. = 117 °C. IR (ATR): 3144m, 3116m, 3036m, 2958s, 2927s, 2870s, 1694s, 1590s, 1542s, 
1443m, 1380m, 1349m, 1306w, 1269s, 1172m, 1099w, 1052w, 976w, 892w, 810m, 769w cm−1. 1H NMR (500 
MHz, CDCl3, δ): 10.15 (bs, 1H), 7.80 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.43 (dd, J1 = 8.5 Hz, J2 = 
1.8 Hz, 1H), 2.98 – 2. 95 (m, 2H), 2.49 – 2. 46 (m, 2H), 1.74 – 1.68 (m, 2H), 1.67 – 1.61 (m, 2H), 1.50 – 1.34 
(m, 4H), 0.94 – 0.89 (m, 6H). 13C NMR (125 MHz, CDCl3, δ): 171.61, 158.86, 146.39, 132.87, 132.45, 128.53, 
122.31, 120.55, 36.22, 34.53, 31.21, 26.94, 22.16, 21.86, 13.61, 13.59. (+) ESI-HRMS: m/z 323.12407 
corresponds to molecular formula C16H22N2OS2H+ (error, -1.73 ppm). HPLC purity, method A: tR = 12.200, 
area 96.72%. Method B: tR =13.409, area 98.18%. 
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N-[6-(butylsulfanyl)-1,3-benzothiazol-2-yl]-2-methoxyacetamide (43).  
The general procedure E was followed using a solution of methoxyacetyl 
chloride (51.5 mg, 0.474 mmol) in benzene (1 mL) and a solution of 20 
(70.7 mg, 0.296 mmol) in CH2Cl2/benzene (2.2 mL, 1:1, v/v). The reaction 
mixture was stirred for 4 h at 0°C, then 13 h at room temperature and worked up according to general 
procedure. The crude product was subjected to silica gel column chromatography using hexane/ethyl acetate as 
eluent to afford 41.3 mg of final product as pale yellow solid. Yield 45 %. M.p. = 62 °C. IR (ATR): 3382w, 
3207w, 2956m, 2929m, 2871w, 1703m, 1594m, 1537s, 1448m, 1272m, 1196w, 1119m, 994w, 817w, 745w 
cm−1. 1H NMR (500 MHz, CDCl3, δ): 9.86 (bs, 1H), 7.79 – 7.78 (m, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.43 (dd, J1 = 
8.5 Hz, J2 = 1.8 Hz, 1H), 4.16 (s, 2H), 3.52 (s, 3H), 2.97 – 2.94 (m, 2H), 1.67 – 1.61 (m, 2H), 1.49 – 1.42 (m, 
2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3, δ): 168.07, 156.52, 146.85, 133.03, 132.65, 128.58, 
122.18, 121.26, 71.25, 59.57, 34.55, 31.24, 21.89, 13.61. (+)ESI-HRMS: m/z 311.08743 corresponds to 
molecular formula C14H18N2O2S2H+ (error, -2.62 ppm). HPLC purity, method A: tR = 10.999, area 98.02%. 
Method B: tR = 12.336, area 98.37%. 
3-Methoxy-N-[6-(propylsulfanyl)-1,3-benzothiazol-2-yl]propanamide (44)  
The general procedure E was followed using a solution of 3-
methoxypropionyl chloride (106 mg, 0.869 mmol) in benzene (1.5 mL) and a 
solution of 19 (150 mg, 0.67 mmol) in CH2Cl2/benzene (2 mL, 1:1, v/v). The 
reaction mixture was stirred for 18 h and worked up according to general procedure. The crude product was 
subjected to silica gel column chromatography using hexane/ethyl acetate as eluent, reversed-phase flash 
chromatography, Biotage SP1, using ethanol/water as eluent and NH flash chromatography, Biotage SP1, using 
hexane/ethyl acetate as eluent to afford 63.2 mg of final product as white solid. Yield 30%. M.p. = 111 °C. IR 
(ATR): 3270w, 3118m, 3038m, 2962s, 2922s, 2811m, 1704m, 1591s, 1544s, 1447m, 1394m, 1270s, 1174m, 
1120m, 1067m, 810m cm−1. 1H NMR (500 MHz, CDCl3, δ): 10.26 (bs, 1H), 7.79 (d, J = 1.8 Hz, 1H), 7.69 (d, J 
= 8.5 Hz, 1H), 7.43 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 3.76 (t, J = 5.5 Hz, 2H),  3.48 (s, 1H), 2.93 (t, J = 7.3 Hz, 
2H), 2.77 (t, J = 5.5 Hz, 2H), 1.71  ̶  1.64 (m, 2H), 1.03 (t, J = 7.3 Hz, 3H).13C NMR (125 MHz, CDCl3, δ): 
169.86, 157.57, 146.97, 133.08, 132.12, 128.67, 122.39, 121.02, 67.67, 59.20, 36.96, 36.90, 22.56, 13.37. 
(+)ESI-HRMS: m/z 311.08741 corresponds to molecular formula C14H18N2O2S2H+ (error, -2.67 ppm). HPLC 
purity, method A: tR = 10.325, area 98.09%. Method B: tR = 11.326, area 99.00%. 
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N-[6-(butylsulfanyl)-1,3-benzothiazol-2-yl]-3-methoxypropanamide (45)  
The general procedure E was followed using a solution of 3-
methoxypropionyl chloride (163.8 mg, 1.342 mmol) in in benzene (2 mL) 
and a solution of 20 (200 mg, 0.839 mmol) in CH2Cl2/benzene (4.4 mL, 1:1, 
v/v). The reaction mixture was stirred for 6 h at 0°C, then 16 h at room temperature and worked up according to 
general procedure. The crude product was subjected to silica gel column chromatography using hexane/ethyl 
acetate and multiple reversed-phase column chromatography using methanol/water as eluent to afford 86.9 mg 
of final product as pale yellow solid. Yield 32 %. M.p. = 99 °C. IR (ATR): 3147s, 3046m, 2953s, 2924s, 2875s, 
2814m, 1703s, 1592s, 1536s, 1451m, 1417m, 1395m, 1332m, 1267s, 1160s, 1116s, 1068m, 988w, 960m, 
808m, 793m, 757m cm−1. 1H NMR (500 MHz, CDCl3, δ): 10.33 (bs, 1H), 7.78 (d, J = 1.6 Hz, 1H), 7.69 (d, J = 
8.5 Hz, 1H), 7.42 (dd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H), 3.77 – 3.74 (m, 2H), 3.47 (s, 3H), 2.97 – 2.94 (m, 2H), 2.78 
– 2.75 (m, 2H), 1.67 – 1.61 (m, 2H), 1.50 – 1.42 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, 
CDCl3, δ): 169.88, 157.62, 146.90, 133.07, 132.24, 128.55, 122.24, 121.00, 67.67, 59.18, 36.90, 34.60, 31.26, 
21.89, 13.62. (+) ESI-HRMS: m/z 325.10332 corresponds to molecular formula C15H20N2O2S2H+ (error, -1.77 
ppm). HPLC purity, method A: tR = 10.636, area 96.78%. Method B: tR = 12.682, area 98.30%.  
2-Methoxy-N-[6-(propylsulfanyl)-1,3-benzothiazol-2-yl]acetamide (46)  
The general procedure E was followed using a solution of methoxyacetyl 
chloride (60.9 mg, 0.561 mmol) in benzene (1 mL) and a solution of 19 (96.8 
mg, 0.431 mmol) in CH2Cl2/benzene (2 mL, 1:1, v/v). The reaction mixture was 
stirred for 2 h at 0°C and worked up according to general procedure. The crude product was subjected to silica 
gel column chromatography using hexane/ethyl acetate as eluent to afford 28.9 mg of final product as pale 
yellow solid. Yield 23 %. M.p. = 62 °C. IR (ATR): 3170m, 3062m, 2966m, 2938m, 2829w, 1688m, 1590m, 
1534s, 1453m, 1273s, 1197m, 1119m, 992w, 809w, 772w, 744w cm−1. 1H NMR (500 MHz, CDCl3, δ): 9.80 
(bs, 1H), 7.79 (d, J = 1.4 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.44 (dd, J1 = 8.5 Hz, J2 = 1.4 Hz, 1H), 4.16 (s, 2H), 
3.52 (s, 3H), 2.93 (t, J = 7.2 Hz, 2H), 1.71 – 1.64 (m, 2H), 1.03 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, 
CDCl3, δ): 168.01, 156.40, 146.99, 133.09, 132.48, 128.67, 122.32, 121.32, 71.22, 59.54, 36.90, 22.53, 13.35. 
(+)ESI-HRMS:m/z 297.07173 corresponds to molecular formula C13H16N2O2S2H+ (error, -2.91 ppm). HPLC 
purity, method A: tR = 10.423, area 97.81%. Method B: tR = 11.602, area 98.30%.  
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Table S1. In vitro antiproliferative activity (GI50, µM) against a panel of 60 cell linesa 
Panel/Cell line 24 25 26 28 29 30 33 
Leukemia        
CCRF-CEM 26.8 3.33 >100 2.98 0.66 0.39 0.63 
HL-60 (TB) 22.4 1.17 >100 0.26 0.27 0.31 0.35 
K-562 2.48 0.39 >100 0.40 0.29 0.28 0.39 
MOLT-4 3.07 3.26 >100 0.94 0.60 0.47 0.85 
RPMI-8226 32.4 2.91 >100 1.56 1.29 0.50 1.04 
SR 10.9 0.54 >100 0.43 0.27 0.19 0.27 
Non-Small Cell Lung 
Cancer 
       
A549/ATCC 17.1 0.83 >100 0.98 0.67 0.64 2.37 
EKVX N.T. N.T. N.T. N.T. N.T. 1.27 0.56 
HOP-62 20.8 3.80 >100 35.5 4.72 0.82 0.49 
HOP-92 N.T. N.T. N.T. 0.39 1.04 0.41 1.44 
NCI-H226 32.2 15.2 >100 >100 1.53 1.03 1.95 
NCI-H23 53.7 6.92 >100 >100 4.48 0.90 1.15 
NCI-H322M 24.1 6.37 >100 1.97 2.06 0.95 5.10 
NCI-H460 18.7 2.44 >100 0.46 0.42 0.40 0.52 
NCI-H522 14.0 0.31 >100 1.00 0.93 0.32 0.24 
Colon Cancer        
COLO 205 38.5 1.75 >100 0.80 0.38 0.26 0.53 
HCC-2998 35.8 8.33 >100 >100 37.8 6.80 4.88 
HCT-116 22.0 0.79 >100 0.47 0.43 0.37 0.47 
HCT-15 20.1 0.67 >100 0.50 0.41 0.44 0.38 
HT29 11.5 0.38 >100 0.40 0.38 0.34 0.35 
KM12 16.3 0.76 >100 0.41 0.38 0.37 0.41 
SW-620 11.7 0.55 >100 0.41 0.37 0.37 0.45 
CNS Cancer        
SF-268 29.4 4.60 >100 18.5 1.45 15.8 0.87 
SF-295 17.8 1.53 >100 0.64 0.34 0.39 0.39 
SF-539 31.2 1.99 >100 0.56 0.27 0.33 0.40 
SNB-19 24.9 5.12 >100 1.57 0.62 0.61 0.78 
SNB-75 18.6 2.07 34.8 1.65 0.12 0.23 0.41 
U251 19.6 1.62 >100 0.68 0.49 0.46 0.41 
Melanoma        
LOXIMVI N.T. N.T. N.T. 1.13 0.63 0.56 0.46 
MALME-3M 24.6 2.70 >100 0.52 N.T. 6.06 0.51 
M14 28.6 0.62 >100 0.56 0.32 0.34 0.45 
MDA-MB-435 1.48 0.20 17.5 0.17 0.12 0.07 0.19 
SK-MEL-2 N.T. N.T. N.T. 0.63 0.44 0.31 0.43 
SK-MEL-28 27.4 5.46 >100 2.72 0.96 2.81 66.2 
SK-MEL-5 30.9 1.81 >100 1.25 0.39 0.37 0.66 
UACC-257 39.0 2.70 >100 >100 0.87  >100 
UACC-62 20.0 1.32 >100 0.42 0.55 0.44 0.32 
Ovarian Cancer        
IGROV1 23.8 3.19 >100 0.62 1.46 1.30 0.94 
OVCAR-3 20.4 1.87 >100 0.44 0.35 0.37 0.35 
OVCAR-4 30.6 6.94 >100 >100 2.45 0.87  
OVCAR-5 43.7 6.75 >100 18.4 6.84 1.81 2.73 
OVCAR-8 28.2 4.16 >100 >100 1.76 1.78 4.85 
NCI/ADR-RES 23.1 0.95 >100 0.61 0.45 0.40 0.36 
SK-OV-3 22.7 5.32 >100 2.47 0.64 0.40 0.54 
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Renal Cancer        
786-0 29.1 4.56 >100 2.32 0.53 0.39 0.54 
A498 13.7 0.67 >100 0.27 0.13 0.12 1.22 
ACHN 42.3 7.19 >100 36.0 0.91 0.82 0.91 
CAKI-1 40.2 3.54 >100 N.T. 0.59 0.59 0.63 
RXF 393 0.21 N.T. 23.0 >100 0.90 0.88 1.03 
SN12C 23.7 3.10 >100 0.91 0.65 0.73 0.96 
TK-10 22.8 4.48 >100 >100 8.44 2.91 2.25 
UO-31 27.3 4.28 >100 2.22 1.05 0.60 1.39 
Prostate Cancer        
PC-3 26.9 4.64 >100 0.96 0.73 0.55 0.80 
DU-145 28.4 5.75 >100 >100 2.37 1.27 1.72 
Breast Cancer        
MCF-7 15.7 0.88 27.6 0.47 0.35 0.31 0.30 
MDA-MB-231/ATCC 14.8 2.37 >100 0.94 1.28 0.58 0.95 
HS 578T 19.4 2.17 >100 1.38 0.45 0.52 0.94 
BT-549 29.9 2.23 >100 0.72 0.76 0.42 0.49 
T-47D 33.3 3.55 >100 17.6 1.68 0.24 0.58 
MDA-MB-468 16.4 1.26 0.20 0.55 0.30 0.49 0.56 
        
MIDb 19.9 2.13 81.2 2.14 0.74 0.58 0.83 
a Five dose assay was performed against 60 cancer cell lines treated with selected compounds for 48 hours using SRB procedure  
bMID = Mean GI50 values for each compound against full 60-cell panel 
N.T.  – not tested 
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Table S2. IC50 values calculated for 25, 26, 28 – 30, 32, 33 – 37 and 41 – 46 using MTT assayc 
Comp. Structure MCF-7 (IC50, µM) 
A375 
(IC50, µM)
K562 
(IC50, µM) NT2/D1 (IC50, µM) MRC-5 (IC50, µM)
25 SN
S
NH
O
O  61.4±4.2 85.0±5.6 >100 >1 - 
26 SN
O
NH
O
O  >100 >100 >100 - - 
28 SN
S
NH
O
O  24.2±3.1 >100 >100 0.2±0.03 > 300 
29 SN
S
NH
O
O  >100 91.6±6.0 >100 >1 - 
30 SN
S
NH
O
O  >100 45.2±3.4 >100 0.1±0.01 >300 
32 SN
S
NH
O
O  >100 - - >1 - 
34 SN
S
NH
O
O  >100 - - >1 - 
35 S
N
S
NH
O
O
 >100 - - >1 - 
36 S
N
S
NH
O
O
 >100 >100 7.7±2.0 >1 - 
37 S
N
S
NH
O
O
 >100 - - >1 - 
39 S
N
S
N
O
OO
H  > 100 - - - - 
40 S
N
S
N
O
OO
HO  > 100 - - - - 
41 S
N
S
NH
O
 30.5±2.5 77.5±4.5 53.2±4.0 >1 > 300 
42 S
N
S
N
O
H  >100 >100 >100 >1 - 
43 SN
S
NH
O O  >100 >100 >100 >1 - 
44 S
N
S
NH
O O
 95.5±5.5 >100 66.3±4.2 >1 - 
45 S
N
S
N
O
O
H  92.5±5.0 >100 44.2±3.3 >1 - 
46 SN
S
NH
O O  >100  >100  >100  >1 - 
Doxorubicin  0.4 - 2 - - 
Cisplatin  - - - 1.11±0.17 - 
cIC50 values were calculated after 48 h treatment of selected cell lines with five concentrations of investigated compounds using MTT 
assay. The measurements were performed in triplicate.   
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Evaluation of antiproliferative effects of compounds 28 and 30 on NT2/D1 cell line 
 
 
Figure S1. Cell cycle phase distribution after 24 h treatment of NT2/D1 cells with compounds 28 and 30 (M1 – 
sub G1, M2 – G0/G1, M3 – S, M4 – G2/M). 
 
 
Figure S2. Mitochondrial membrane potential (MMP) in NT2/D1 cells after 48 h treatment with 28 and 30 
compared to control cells’ MMP 
 
Figure S3.  Intracellular ROS level in NT2/D1 cells after 48 h treatment with compounds 28 and 30 at 1 µM 
compared to control cells. 
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Table S3. Non-tumored animal toxicity assay for compound 28 
 
 
 
Table S4. Non-tumored animal toxicity assay for compound 30 
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